Sharon Barton

Senior Director Biostatistics, Clinical Development
Freeline

Presentation(s):

• PB0213 - Results from B-LIEVE, a Phase 1/2 Dose-Confirmation Study of FLT180a AAV Gene Therapy in Patients with Hemophilia B

  Sunday, July 10, 2022
  6:30 PM – 7:30 PM